EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Non-Steroidal LXR Agonists; An Emerging Therapeutic Strategy for the Treatment of Atherosclerosis

David J Bennett, Andrew J Cooke, Andrew S Edwards

Recent Patents on Cardiovascular Drug Discovery · 2006

DOI: 10.2174/157489006775244245 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Recent Patents on Cardiovascular Drug Discovery, 2006. Verfasst von David J Bennett und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Organon Laboratories Ltd., Newhouse ML1 5SH, Scotland, UK. j.bennett@organon.co.uk. Die Arbeit wurde bisher 23-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Liver X Receptor (LXR) alpha and beta isoforms are members of the type II nuclear receptor family which function as obligate heterodimers with the Retinoid X Receptor (RXR). Upon agonist binding, the DNA Binding Domain (DBD) of LXR interacts with LXR response elements on target genes to initiate transcription. A number of genes have been shown to be modulated by LXR function, including the ATP-binding cassette transporter A1 (ABCA1). ABCA1 is involved in the process of reverse cholesterol transport (RCT) from macrophages in atherosclerotic plaques to high-density lipoproteins (HDL) in the plasma. Both homozygous and heterozygous mutations in ABCA1 result in conditions characterised by decreased levels of HDL and an earlier onset of atherosclerosis. A number of other genes are upregulated by LXR activation which would be expected to have either pro- or anti-atherogenic effects. One such target gene is sterol regulatory element binding protein-1c (SREBP-1c), which is involved in the process of lipogenesis leading to increased levels of triglycerides which are pro-atherogenic. The complexity of LXR responses, however, makes it difficult to extrapolate the 'positive' or 'negative' effects of each target gene in isolation to a conclusion as to the outcome in humans when all target genes are being modulated in concert. This review will cover the structural features and associated biological data of non-steroidal LXR modulators claimed for the treatment of cardiovascular disease, as well as highlighting preferred compounds where this information can be discerned. In addition to this patent information a précis of literature data relevant to the utility of specific compounds in the treatment of cardiovascular disease will be given where available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ATP Binding Cassette Transporter 1ATP-Binding Cassette TransportersAcetyl-CoA CarboxylaseAnimalsAtherosclerosisDNA-Binding ProteinsFatty Acid SynthasesHumansHydrocarbons, FluorinatedLiver X ReceptorsOrphan Nuclear ReceptorsOsteopontinReceptors, Cytoplasmic and NuclearSterol Regulatory Element Binding Protein 1SulfonamidesThromboplastinFluorocarbonsBenzenesulfonamides

Substanzen

ATP Binding Cassette Transporter 1ATP-Binding Cassette TransportersAcetyl-CoA CarboxylaseDNA-Binding ProteinsFatty Acid SynthasesHydrocarbons, FluorinatedLiver X ReceptorsOrphan Nuclear ReceptorsOsteopontinReceptors, Cytoplasmic and Nuclear

Autor:innen und Institutionen

  • Department of Chemistry, Organon Laboratories Ltd., Newhouse ML1 5SH, Scotland, UK. j.bennett@organon.co.uk

Zitieren

APA

Bennett, D. J., Cooke, A. J., & Edwards, A. S. (2006). Non-Steroidal LXR Agonists; An Emerging Therapeutic Strategy for the Treatment of Atherosclerosis. Recent Patents on Cardiovascular Drug Discovery. https://doi.org/10.2174/157489006775244245

Vancouver

Bennett DJ, Cooke AJ, Edwards AS. Non-Steroidal LXR Agonists; An Emerging Therapeutic Strategy for the Treatment of Atherosclerosis. Recent Patents on Cardiovascular Drug Discovery. 2006. doi:10.2174/157489006775244245

BibTeX
@article{Bennett2006,
  author = {Bennett, David J and Cooke, Andrew J and Edwards, Andrew S},
  title = {Non-Steroidal LXR Agonists; An Emerging Therapeutic Strategy for the Treatment of Atherosclerosis},
  journal = {Recent Patents on Cardiovascular Drug Discovery},
  year = {2006},
  doi = {10.2174/157489006775244245}
}
Kostenlos starten →